Quick Answer
Bofanglutide is a new GLP-1 injection given every two weeks instead of weekly. A June 2026 trial showed it lowers blood sugar and aids weight loss — potentially a game-changer for needle-averse Indian patients.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
If you or someone you care for has been avoiding GLP-1 medications like Ozempic or Mounjaro because of the commitment to a weekly injection, important new research may change the picture. A clinical trial published on June 30, 2026 in the Annals of Internal Medicine found that a new GLP-1 medication called bofanglutide — administered just once every two weeks instead of once every week — effectively lowers blood sugar and supports weight loss in people with type 2 diabetes. For Indian patients who are needle-averse, live far from cities, or find the weekly injection schedule difficult to maintain, this development deserves close attention.
What Is Bofanglutide?
Bofanglutide is a new GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals, a Chinese biopharmaceutical company with a focus on diabetes treatment. It works through the same biological mechanism as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — by activating the GLP-1 receptor in the brain and gut to reduce appetite, slow stomach emptying, lower blood sugar, and promote weight loss. What makes bofanglutide different is its injection frequency: it is designed to be given once every two weeks, compared to the once-weekly schedule of existing GLP-1 drugs.
This is not merely a convenience upgrade. For many patients — particularly those in rural or semi-urban parts of India who may visit a clinic fortnightly rather than weekly, or those who find frequent self-injection psychologically difficult — a biweekly dosing schedule could be the difference between starting treatment and not starting it at all.
What the Trial Found
The phase 2b randomised clinical trial enrolled 272 adults with type 2 diabetes across 37 sites in China. Participants were divided into five groups: three groups received different doses of biweekly bofanglutide (12 mg, 18 mg, or 24 mg), one group received 24 mg bofanglutide once weekly, and the fifth group received 1 mg semaglutide once weekly as the comparator drug. The trial ran for 24 weeks.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
The primary outcome measured was reduction in HbA1c — the standard three-month average blood sugar marker used to assess diabetes control. All three biweekly bofanglutide groups showed significant and clinically meaningful reductions in HbA1c from baseline. Participants also experienced weight loss and improvements in cardiometabolic risk factors including blood pressure and cholesterol markers. Notably, some bofanglutide groups achieved slightly greater blood sugar reductions than the semaglutide comparison group, although researchers cautioned that the semaglutide dose used in the trial (1 mg) was at the lower end of the approved range, meaning direct comparisons require further study.
Side effects were consistent with what is known about the GLP-1 drug class — mainly nausea and gastrointestinal symptoms — and were described as generally mild. This is in line with what patients experience on weekly GLP-1 drugs like Ozempic and Mounjaro.
Why This Matters for Indian Patients Specifically
India has approximately 77 million adults living with type 2 diabetes — the second largest diabetic population in the world — and another large group of people living with obesity-related health conditions who could benefit from GLP-1 therapy. Despite the dramatic price drop in GLP-1 medications following the Indian semaglutide patent expiry in March 2026, one persistent barrier to treatment uptake remains psychological and logistical: the weekly injection.
For many Indian patients, particularly those unfamiliar with self-injection or those who receive injections from a local health worker or clinic, a weekly schedule creates real friction. Patients in smaller towns or rural areas may not be able to visit a healthcare facility every week. Elderly patients or those with limited hand dexterity may find frequent injections difficult to manage alone. And for a significant subset of patients across all demographics, needle anxiety is a genuine barrier — not a trivial concern.
A once-every-two-weeks option would halve the number of injections per year and could make GLP-1 therapy accessible to patients who might otherwise have declined or abandoned treatment. It would also align more naturally with many Indian patients' existing patterns of clinical follow-up.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
The China-India relevance is also significant here. The bofanglutide trial was conducted in a Chinese population — and South Asian and East Asian populations share important metabolic similarities. Both populations tend to develop type 2 diabetes and obesity-related conditions at lower body weights and BMIs than Western populations, develop insulin resistance at younger ages, and have higher rates of visceral fat relative to overall body weight. Trial results from Chinese diabetic populations are more likely to generalise to Indian patients than results from predominantly Western cohorts.
Where Does Bofanglutide Stand Right Now?
Bofanglutide is currently in Phase 2b clinical trials. This means it has demonstrated safety and efficacy in a controlled setting, but has not yet completed the larger Phase 3 trials required for regulatory approval in any country. For context, the path from Phase 2b results to approval and commercial availability typically takes three to five years, depending on the regulatory authority and how quickly Phase 3 trials progress.
Bofanglutide is not yet approved by India's DCGI (Drug Controller General of India), the US FDA, or any other major regulatory body. Indian patients cannot currently access it through normal prescription channels. However, the published trial results are a meaningful signal that the once-every-two-weeks GLP-1 approach is scientifically viable and is being actively developed.
Medical experts who reviewed the study for Healthline noted the limitations: the trial was 24 weeks in duration (relatively short for a diabetes treatment), enrolled only 272 participants, and was conducted exclusively in a Chinese cohort. Larger and longer Phase 3 trials with more diverse populations will be needed before any regulatory body will consider approval.
What This Means for You Today
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
If you have type 2 diabetes or obesity and have been putting off starting a GLP-1 medication because the weekly injection seems like too much, the important message from the bofanglutide research is that pharmaceutical development is actively moving in the direction of less frequent injections. The current generation of once-weekly GLP-1 drugs represents one step. The next generation — including biweekly options — is already in the pipeline.
In the meantime, if cost or injection frequency is holding you back from GLP-1 therapy, it is worth knowing that options have improved significantly in India in 2026. Generic semaglutide is now available at prices starting from approximately Rs 1,290 per month. An experienced GLP-1 specialist can guide you through the options — including the correct starting dose, injection technique, and a plan to manage the most common side effects — so that beginning weekly treatment is far less daunting than it may seem.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. Healthline — https://www.healthline.com/health-news/biweekly-glp-1-shot-improves-blood-sugar-weight-loss-clinical-trial 2. Annals of Internal Medicine (trial publication) — https://www.acpjournals.org/doi/10.7326/ANNALS-25-04623 3. CNBC India (generic semaglutide context) — https://www.cnbc.com/2026/03/23/novo-nordisk-cheap-weight-loss-drugs-india-generic-ozempic-wegovy-semaglutide.html
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.